SCHEMBL5454151

SCHEMBL5454151

Cc1cccc(NC(=O)Nc2sc3c(c2C(N)=O)CCSC3)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 2/20 0.53
TNIK Q9UKE5 1/20 0.50
MAPT P10636 7/20 0.48
LMNA P02545 2/20 0.48
TP53 P04637 1/20 0.47
BLM P54132 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
EPHB4 P54760 1/20 0.47
KDM4E B2RXH2 1/20 0.46
USP2 O75604 1/20 0.46
HTT P42858 1/20 0.46
ATM Q13315 1/20 0.46
ALDH1A1 P00352 1/20 0.46
GAA P10253 1/20 0.46
THRB P10828 1/20 0.45
KCNH2 Q12809 4/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5467572 0.88 FLT3 (0.53) FLT3TNIKMAPTLMNATP53
SCHEMBL5462915 0.88 TNIK (0.48) FLT3TNIKMAPTLMNATP53
SCHEMBL5452256 0.87 TLR2 (0.53) FLT3TNIKMAPTLMNATP53
SCHEMBL5467554 0.87 FLT3 (0.56) FLT3TNIKMAPTLMNATP53
SCHEMBL8288770 0.86 FLT3 (0.68) FLT3MAPTLMNATP53BLM
SCHEMBL5453264 0.86 FLT3 (0.71) FLT3MAPTLMNATP53BLM
SCHEMBL5462800 0.85 KMT2A (0.48) TNIKMAPTLMNATP53MEN1
SCHEMBL5453512 0.84 FLT3 (0.50) FLT3TNIKMAPTSMN1; SMN2NPC1
SCHEMBL5451652 0.82 CFTR (0.60) FLT3TNIKMAPTLMNATP53
SCHEMBL5449415 0.82 MEN1 (0.64) TNIKMAPTLMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 FLT3 3509/4885TNIK 4134/4885MAPT 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.